Dr. Stadler on the Therapeutic Landscape of RCC

Video

In Partnership With:

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

In the last 10 years or so, physicians have relied on VEGFR-targeted therapies in RCC, including pazopanib (Votrient), sunitinib (Sutent), and axitinib (Inlyta). Now, physicians are moving into an era of immunotherapy, which includes nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), and avelumab (Bavencio), enabling researchers to look at combination approaches.

Part of the rationale of exploring combinations of VEGF and immunotherapy agents is their accessibility, says Stadler. However, there is a scientific rationale for their use in combination as well. For example, some of the VEGF pathways have been shown to be immunosuppressive and may induce immunosuppressive properties, says Stadler. Some of the combinations that have been shown to be effective to date include axitinib and avelumab, axitinib and pembrolizumab, and atezolizumab and bevacizumab (Avastin).

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,